Share-split context: A forward split was recorded on Feb 14, 2012 with coefficient 3.000003. A forward split turns each old share into multiple new shares and lowers the quoted price per share proportionally. Proportional ownership is unchanged at the split moment, so the split itself creates neither a gain nor a loss. The price-return figures in this report are already split-adjusted.

What this ETF is trying to do

The VanEck Biotech ETF (BBH) focuses on the biotechnology industry. It holds a variety of companies that work on medical technology and biological medicines. Based on the Top Holdings list from October 8, 2026, the fund is heavily invested in companies like Amgen Inc (15.74%), Gilead Sciences Inc (13.28%), and Vertex Pharmaceuticals Inc (8.22%).

What the numbers show

The performance numbers for this ETF are split-adjusted. This means the data accounts for a "forward split" that happened on February 14, 2012. In a forward split, each old share becomes multiple new shares, and the price per share drops proportionally. This change does not create a gain or a loss; it just changes how many shares a person owns.

Here is the performance based on the supplied data:

• Year-to-Date (YTD): The price return and total return are both 25.68%.

• One Year: The price return (share-price movement) was 36.36%, while the total return (which includes distributions) was 37.04%.

• Three Year: The price return was 52.34%, and the total return was 54.99%.

• Five Year: The total return was 25.82%.

Income and distribution explanation

This ETF has a distribution yield of approximately 0.40%. It pays out distributions irregularly and less frequently, with only one payout in the last 12 months.

It is important for new investors to remember that a distribution yield is not the same as a total return. While distributions provide cash income, they do not guarantee that the original investment value will stay the same.

NAV erosion explanation

"NAV erosion" happens when the actual value of the fund's underlying assets drops over time. StockValueFinder uses an erosion-risk score to measure this.

For BBH, the erosion score is 100, and the label is "No price erosion detected." The erosion severity is listed as "good," and there is no severe erosion-risk flag.

Pros

• Strong Growth: The ETF has shown positive price and total returns over the one-year and three-year periods.

• Low Erosion Risk: The fund currently has a "good" erosion severity rating.

Cons

• Low Income: The distribution yield is very low (0.40%), which may not be ideal for investors seeking high cash income.

• Irregular Payouts: Distributions are not paid on a steady, predictable schedule.

Beginner takeaway

The VanEck Biotech ETF is designed for those who want exposure to biotech companies. While it has seen significant price growth recently, it provides very little cash income. Investors should focus on the total return rather than the distribution yield to see how the fund is performing overall.